Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,097
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients

Francesco Piscazzia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Luigi Gargiuloa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Luciano Ibbaa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyCorrespondence[email protected]
View further author information
,
Mario Valentia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Paola Facherisb Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
,
Antonio Costanzoa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
&
Alessandra Narcisib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
 show all
Article: 2245510 | Received 03 May 2023, Accepted 31 Dec 2023, Published online: 09 Aug 2023

References

  • Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):1–3. doi: 10.1016/j.clindermatol.2018.05.007.
  • Facheris P, Da Rosa JC, Pagan AD, et al. Age of onset defines two distinct profiles of atopic dermatitis in adults. Allergy. 2023;78(8):2202–2214. doi: 10.1111/all.15741.
  • Gargiulo L, Piscazzi F, Ibba L, et al. Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience. J Dermatolog Treat. 2023;34(1):2192840. doi: 10.1080/09546634.2023.2192840.
  • Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345.
  • Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther. 2023;13(2):651–660. doi: 10.1007/s13555-022-00882-z.
  • Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2.
  • Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4.Erratum in: lancet. 2021 Jun 19;397(10292):2336. Erratum in: lancet. 2021 Aug 28;398(10302):746.
  • Rinvoq_EPAR - Product Information as approved by the CHMP on 23. January 2023. Available from https://www.ema.europa.eu/en/documents/referral/rinvoq-epar-product-information-approved-chmp-23-january-2023-pending-endorsement-european_en.pdf.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.